翻訳と辞書 |
Ephraim Heller : ウィキペディア英語版 | Ephraim Heller Ephraim Heller is a prolific inventor and entrepreneur, and the current CEO of SynAgile Corporation.〔http://www.synagilepharma.com〕 SynAgile is developing new therapies for treatment of Parkinson's disease. In 1992, he was the co-founder and first CEO of TheraSense, which went〔(【引用サイトリンク】title=THERASENSE INC (Form: S-1, Received: 10/11/2000 17:35:49) )〕 public and was later sold to Abbott Labs for $1.2 billion.〔http://www.nytimes.com/2004/01/14/business/the-markets-stocks-bonds-corporate-earnings-jitters-send-shares-modestly-lower.html?scp=4&sq=%22therasense%22&st=cse〕 He was also co-founder, chairman and CEO of AngioScore and led the product development and FDA approval. AngioScore was acquired in 2014 for $230 million plus milestone payments. Prior to its acquisition, the company sold more than 300,000 AngioSculpt catheters in over 65 countries around the world. He was previously a Venture Partner at 7 Health Ventures. Heller holds an MBA from Yale School of Management and he has an AB in Physics from Harvard. == Patents == Ephraim Heller holds over 100 US patents, including patents on blood glucose monitors and photocatalytic materials.〔http://search.usa.gov/search?affiliate=web-sdmg-uspto.gov&commit=Search&embedded=&filter=moderate&locale=en&m=&page=2&query=%22heller%2C+ephraim%22&sc=0&utf8=✓〕
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Ephraim Heller」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|